Equities research analysts at Royal Bank Of Canada started coverage on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a research note issued to investors on Thursday, The Fly reports. The firm set an “outperform” rating on the biopharmaceutical company’s stock.

Several other research firms also recently commented on ALXN. Barclays PLC reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. UBS AG reiterated a “buy” rating and set a $142.00 target price (up previously from $140.00) on shares of Alexion Pharmaceuticals in a research report on Monday, June 26th. Deutsche Bank AG cut their target price on Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Thursday, May 25th. Morgan Stanley reiterated an “overweight” rating and set a $153.00 target price (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research report on Friday, July 28th. Finally, J P Morgan Chase & Co upgraded Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $163.00 to $175.00 in a research report on Tuesday, September 5th. Five investment analysts have rated the stock with a hold rating, twenty have given a buy rating and three have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $157.74.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.26% on Thursday, hitting $144.62. The stock had a trading volume of 1,249,895 shares. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $149.34. The firm has a 50-day moving average price of $137.59 and a 200-day moving average price of $124.34. The stock has a market capitalization of $32.28 billion, a P/E ratio of 62.71 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The firm had revenue of $912.00 million for the quarter, compared to the consensus estimate of $846.15 million. During the same quarter last year, the company earned $1.13 earnings per share. The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. Equities analysts expect that Alexion Pharmaceuticals will post $5.61 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/09/14/royal-bank-of-canada-initiates-coverage-on-alexion-pharmaceuticals-inc-alxn.html.

In related news, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares of the company’s stock, valued at approximately $3,738,560. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the sale, the director now directly owns 6,315 shares of the company’s stock, valued at $869,828.10. The disclosure for this sale can be found here. Insiders have sold a total of 17,070 shares of company stock valued at $2,416,869 over the last three months. 4.35% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of the stock. Guardian Life Insurance Co. of America lifted its stake in shares of Alexion Pharmaceuticals by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 6 shares during the last quarter. Eqis Capital Management Inc. raised its position in Alexion Pharmaceuticals by 0.6% during the 2nd quarter. Eqis Capital Management Inc. now owns 6,776 shares of the biopharmaceutical company’s stock valued at $824,000 after purchasing an additional 38 shares in the last quarter. Rathbone Brothers plc raised its position in Alexion Pharmaceuticals by 2.5% during the 2nd quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 50 shares in the last quarter. Cleararc Capital Inc. raised its position in Alexion Pharmaceuticals by 1.0% during the 1st quarter. Cleararc Capital Inc. now owns 5,495 shares of the biopharmaceutical company’s stock valued at $666,000 after purchasing an additional 53 shares in the last quarter. Finally, Seven Bridges Advisors LLC raised its position in Alexion Pharmaceuticals by 2.1% during the 2nd quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 53 shares in the last quarter. 94.26% of the stock is owned by hedge funds and other institutional investors.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

The Fly

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.